EP Patent

EP3587421A1 — Crystalline forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-alpha]pyrazin-1-yl-n-(pyridin-2-yl)benzamide

Assigned to Sandoz AG · Expires 2020-01-01 · 6y expired

What this patent protects

The present invention relates to crystalline acalabrutinibL-pyroglutamate and crystalline acalbrutinib L-malate and to processes for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising one of said crystalline forms, preferably in a pre…

USPTO Abstract

The present invention relates to crystalline acalabrutinibL-pyroglutamate and crystalline acalbrutinib L-malate and to processes for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising one of said crystalline forms, preferably in a predetermined and/or effective amount and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of cancers such as mantle cell lymphoma and/or chronic lymphocytic leukaemia.

Drugs covered by this patent

Patent Metadata

Patent number
EP3587421A1
Jurisdiction
EP
Classification
—
Expires
2020-01-01
Drug substance claim
No
Drug product claim
No
Assignee
Sandoz AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.